These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 35669313

  • 21. Comparative assessment of the effects of subdermal levonorgestrel implant system and long acting progestogen injection method on lipid metabolism.
    Anwar M, Soejono SK, Maruo T, Abdullah N.
    Asia Oceania J Obstet Gynaecol; 1994 Mar; 20(1):53-8. PubMed ID: 8172528
    [Abstract] [Full Text] [Related]

  • 22. Influence of Hormonal Contraceptive Use and HIV on Cervicovaginal Cytokines and Microbiota in Malawi.
    Haddad LB, Tang JH, Davis NL, Kourtis AP, Chinula L, Msika A, Tegha G, Hosseinipour MC, Nelson JAE, Hobbs MM, Gajer P, Ravel J, De Paris K.
    mSphere; 2023 Feb 21; 8(1):e0058522. PubMed ID: 36622252
    [Abstract] [Full Text] [Related]

  • 23. Systems analysis reveals differential expression of endocervical genes in African women randomized to DMPA-IM, LNG implant or cu-IUD.
    Gupta PM, Balle C, Tharp GK, Nelson SA, Gasper MA, Brown B, Alisoltani A, Onono M, Palanee-Phillips T, Nair G, Ayele H, Noel-Romas L, Passmore JS, Burgener AD, Heffron R, Jaspan HB, Bosinger SE.
    Clin Immunol; 2023 Oct 21; 255():109750. PubMed ID: 37660744
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil].
    Yela DA, Monteiro IM, Bahamondes LG, Del Castillo S, Bahamondes MV, Fernandes A.
    Rev Assoc Med Bras (1992); 2006 Oct 21; 52(1):32-6. PubMed ID: 16622536
    [Abstract] [Full Text] [Related]

  • 27. Is long-acting reversible contraceptive method use associated with HIV testing frequency in KwaZulu-Natal, South Africa and Lusaka, Zambia? Findings from the CUBE study.
    Beksinska M, Cartwright AF, Smit J, Kasaro M, Tang JH, Fawzy M, Maphumulo V, Chinyama M, Chabu E, Callahan R.
    Contracept X; 2023 Oct 21; 5():100089. PubMed ID: 36718374
    [Abstract] [Full Text] [Related]

  • 28. Psychological, behavioural and physiological effects of three long-acting reversible contraception (LARC) methods: protocol for an ancillary study of the ECHO randomised trial.
    Singata-Madliki M, Hofmeyr GJ, Carayon-Lefebvre d'Hellencourt F, Lawrie TA.
    BMJ Open; 2017 Nov 12; 7(11):e019205. PubMed ID: 29133336
    [Abstract] [Full Text] [Related]

  • 29. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S, WHO Study Group on Contraceptive Implants for Women.
    Hum Reprod; 2015 Nov 12; 30(11):2527-38. PubMed ID: 26409014
    [Abstract] [Full Text] [Related]

  • 30. Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial.
    Chinula L, Nelson JAE, Wiener J, Tang JH, Hurst S, Tegha G, Msika A, Ellington S, Hosseinipour MC, Mataya R, Haddad LB, Kourtis AP.
    Contraception; 2018 Sep 12; 98(3):193-198. PubMed ID: 29746813
    [Abstract] [Full Text] [Related]

  • 31. Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study).
    Hofmeyr GJ, Morrison CS, Baeten JM, Chipato T, Donnell D, Gichangi P, Mugo N, Nanda K, Rees H, Steyn P, Taylor D, ECHO Trial Team.
    Gates Open Res; 2017 Sep 12; 1():17. PubMed ID: 29355224
    [Abstract] [Full Text] [Related]

  • 32. Hormonal contraception and HIV acquisition among women: an updated systematic review.
    Curtis KM, Hannaford PC, Rodriguez MI, Chipato T, Steyn PS, Kiarie JN.
    BMJ Sex Reprod Health; 2020 Jan 12; 46(1):8-16. PubMed ID: 31919239
    [Abstract] [Full Text] [Related]

  • 33. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
    Todd CS, Jones HE, Langwenya N, Hoover DR, Chen PL, Petro G, Myer L.
    PLoS Med; 2020 May 12; 17(5):e1003110. PubMed ID: 32442189
    [Abstract] [Full Text] [Related]

  • 34. Contraceptive adherence among HIV-infected women in Malawi: a randomized controlled trial of the copper intrauterine device and depot medroxyprogesterone acetate.
    Haddad LB, Cwiak C, Jamieson DJ, Feldacker C, Tweya H, Hosseinipour M, Hoffman I, Bryant AG, Stuart GS, Noah I, Mulundila L, Samala B, Mayne P, Phiri S.
    Contraception; 2013 Dec 12; 88(6):737-43. PubMed ID: 24060297
    [Abstract] [Full Text] [Related]

  • 35. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors.
    Taneepanichskul S, Intaraprasert S, Theppisai U, Chaturachinda K.
    Contraception; 1997 Jul 12; 56(1):1-3. PubMed ID: 9306024
    [Abstract] [Full Text] [Related]

  • 36. Genital inflammatory status and the innate immune response to contraceptive initiation.
    Radzey N, Harryparsad R, Meyer B, Chen PL, Gao X, Morrison C, Taku O, Williamson AL, Mehou-Loko C, Lefebvre d'Hellencourt F, Buck G, Smit J, Strauss J, Nanda K, Ahmed K, Beksinska M, Serrano M, Bailey V, Masson L, Deese J.
    Am J Reprod Immunol; 2022 Aug 12; 88(2):e13542. PubMed ID: 35394678
    [Abstract] [Full Text] [Related]

  • 37. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol.
    Suvanto-Luukkonen E, Sundström H, Penttinen J, Kauppila A.
    Arch Gynecol Obstet; 1998 Aug 12; 261(4):201-8. PubMed ID: 9789651
    [Abstract] [Full Text] [Related]

  • 38. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
    Sivin I, Stern J, Diaz J, Diaz MM, Faundes A, el Mahgoub S, Diaz S, Pavez M, Coutinho E, Mattos CE.
    Contraception; 1987 Mar 12; 35(3):245-55. PubMed ID: 3111785
    [Abstract] [Full Text] [Related]

  • 39. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
    Luukkainen T, Toivonen J.
    Contraception; 1995 Nov 12; 52(5):269-76. PubMed ID: 8585882
    [Abstract] [Full Text] [Related]

  • 40. Copper intrauterine device increases vaginal concentrations of inflammatory anaerobes and depletes lactobacilli compared to hormonal options in a randomized trial.
    Brown BP, Feng C, Tanko RF, Jaumdally SZ, Bunjun R, Dabee S, Happel AU, Gasper M, Nyangahu DD, Onono M, Nair G, Palanee-Phillips T, Scoville CW, Heller K, Baeten JM, Bosinger SE, Burgener A, Passmore JS, Heffron R, Jaspan HB.
    Nat Commun; 2023 Jan 30; 14(1):499. PubMed ID: 36717556
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.